The effect of coagulation factors polymorphisms on abortion

Feizollahi, Narjes; Zayeri, Zeinab Deris; Moradi, Najme; Zargar, Mahvash; Rezaeeyan, Hadi

doi:10.1007/s11515-018-1500-8

Cited by 6 publications

(4 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recurrent spontaneous miscarriage (RSM) is defined as loss of two or more conceptuses before 20 weeks of gestation . It is a significant reproductive problem affecting approximately 1–2% of women who try to conceive .…”

Section: Introductionmentioning

confidence: 99%

“…Recurrent spontaneous miscarriage (RSM) is defined as loss of two or more conceptuses before 20 weeks of gestation. 1 It is a significant reproductive problem affecting approximately 1-2% of women who try to conceive. 2 Although multiple factors like infection, genetics, hormones, uterine/ovary anatomy and antiphospholipid syndrome have been linked to recurrent spontaneous abortion, the causes of 25-50% of RSM occurrence remain unknown.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of vascular endothelial growth factor A polymorphisms and aberrant expression of connexin 43 and VEGFA with idiopathic recurrent spontaneous miscarriage

Sajjadi

Ghandil

Shahbazian

et al. 2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim Idiopathic recurrent spontaneous miscarriage (IRSM) is one of the pregnancy outcomes that affects 1–2% of women trying to conceive. Specific genotype or aberrant expression of vascular endothelial growth factor A (VEGFA) and connexin 43 (Cx43) as two important genes for embryonic development are deemed to increase the risk of IRSM. Methods To investigate any possible association of VEGFA polymorphisms and aberrant expression of Cx43 and VEGFA with IRSM, we carried out a case–control study including embryo chorionic villus tissues of 100 pregnant women with IRSM and 100 embryo chorionic villus tissues of healthy pregnant women without history of miscarriage. Restriction fragment length polymorphism was used for genotyping of rs699947 (−2578C/A) and rs2010963 (−634G/C) polymorphisms in VEGFA. Besides, quantitative real‐time PCR was performed for VEGFA and Cx43 expression analysis. Results The results showed that the frequency of −634G/C and C/C genotypes was significantly higher in aborted fetuses (P = 0.001 and P < 0.001, respectively) compared to the control group's. However, the frequency of −2578C/A genotypes was not significantly different between the cases and controls. Moreover, a significant higher expression of VEGF (P = 0.0005) and Cx43 (P = 0.0011) was observed in chorionic villus tissues of women with IRSM. Conclusion The finding demonstrated that IRSM frequency may depend on GC and CC genotypes of rs2010963 VEGF polymorphism and expression level of VEGF and Cx43 in IRSM patients was increased.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association of vascular endothelial growth factor A polymorphisms and aberrant expression of connexin 43 and VEGFA with idiopathic recurrent spontaneous miscarriage

Sajjadi

Ghandil

Shahbazian

et al. 2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…2 Thrombophilia is caused by genetic or acquired alterations to the coagulation factors or a deficiency in the fibrinolytic pathway, resulting in abnormal clot formation. 3 Both acquired and inherited variables are risk factors for venous thrombosis. Prolonged bed rest, surgery, pregnancy or puerperium, hormone treatment, varicose veins, long flights, acute inflammatory, rheumatological disorders & malignancies are all acquired risk factors.…”

Section: Introductionmentioning

confidence: 99%

Relation between Endothelial Protein C Receptor Gene Polymorphism 6936A/G and the Risk of Vascular Access Thrombosis in Patients with End Stage Renal Disease on Hemodialysis

Emam

Zoheri

Ibrahim

et al. 2022

Al-Azhar International Medical Journal

View full text Add to dashboard Cite

Background:The most significant complication of chronic kidney disease (CKD) is end-stage renal disease (ESRD). Hemodialysis (HD) necessitates a well-functioning vascular access with enough blood flow for clearance and blood dialysis. Thrombosis of the veins can be caused by both acquired and inherited factors. Aim of The Work: To to assess EPCR levels in patients with ESRD on hemodialysis & study relationship between the presence of EPCR gene polymorphisms (6936A/G) and incidence of vascular access thrombosis. Patients and Methods: This research was carried out on 50 studied cases admitted to the Theodor Bilharz Research Institute (TBRI), Imbaba, Giza, Hemodialysis Unit, Nephrology Department from November 2018 to May 2019. In addition, 25 age and sex-matched normal people (control cases) were included. Results: The mutant EPCR (6936A/G) genotypes were found to be substantially more prevalent in our investigation and the polymorphic type allele (G allele) in (p < 0.05) in ESRD patients on long-term hemodialysis with thrombosis compared to healthy subjects and ESRD patients without thrombosis. the flow cytometric expression of CD 201 was statistically reduced in ESRD patients on long-term hemodialysis with thrombosis (p < 00.01) & without thrombosis (p < 00.05) when compared to healthy subjects. CD201 Expression levels showed negative correlation with EPCR 6936 A/G heteromutant genotype. Conclusion: The result obtained via the recurrent study provide evidence that EPCR 6936A/G (rs867186) genetic polymorphisms in ESRD patients on long-term hemodialysis could be a potential reason for Venous thrombosis.

show abstract

“…Aspirin prevents this disorder by inhibiting the TXA2 secretion without affecting prostacyclin secretion. Therefore, the use of aspirin in patients can prevent thrombosis and placental abruption (1,(12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Effect of Aspirin Dose on Preeclampsia Prevention and Fetal-maternal Complications: A Randomized Clinical Trial

Chamani

Shahrabi

Malmir

et al. 2021

Jundishapur J Chronic Dis Care

View full text Add to dashboard Cite

Background: Preeclampsia (PE) is a disease characterized by abnormalities in the placenta and endothelial cells. The pathogenesis is not fully understood; however, aspirin prescription can be effective to treat the disease and prevent fetal developmental disorders. Methods: This study was performed as a clinical trial in Shahid Akbrabadi Hospital in Tehran city. Eighty patients participated in two groups (n = 40). The first group of patients received the dose of 80 mg, and the second group received the dose of 160 mg aspirin. Then, the fetal-maternal and treatment process complications were examined in the patients. Results: The results showed that the incidence of fetal-maternal complications, including intrauterine growth restriction (IUGR) and intrauterine fetal death (IUFD) was lower in patients treated with 160 mg aspirin than in the other group, but this difference was not statistically significant (P-value > 0.05). Aspirin complications such as bleeding were more in the second group than in the first one (P-value < 0.05). Conclusions: Although the increasing dose of aspirin reduces fetal-maternal complications in PE patients, the problems such as aspirin-induced bleeding should be considered.

show abstract

The effect of coagulation factors polymorphisms on abortion

Cited by 6 publications

References 57 publications

Association of vascular endothelial growth factor A polymorphisms and aberrant expression of connexin 43 and VEGFA with idiopathic recurrent spontaneous miscarriage

Association of vascular endothelial growth factor A polymorphisms and aberrant expression of connexin 43 and VEGFA with idiopathic recurrent spontaneous miscarriage

Relation between Endothelial Protein C Receptor Gene Polymorphism 6936A/G and the Risk of Vascular Access Thrombosis in Patients with End Stage Renal Disease on Hemodialysis

Effect of Aspirin Dose on Preeclampsia Prevention and Fetal-maternal Complications: A Randomized Clinical Trial

Contact Info

Product

Resources

About